🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchCan we talk about how SLOW the FDA is Page 4

Can we talk about how SLOW the FDA is

KarenAZ_mom Mon, Apr 20, 2026 at 10:27 AM 38 replies 1,036 viewsPage 4 of 8
Dr.PathRoch
Member
456
2,123
Jun 2024
Rochester, MN
Apr 24, 2026 at 12:41 AM#16

From the other side of the consultation, briefly. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

Last edited: Apr 24, 2026 at 6:41 AM
31 6MikeFit_NJ, InsuranceTom, WendyG_ATL and 28 others
Reply Quote Save Share Report
Dr.KarenChen
VIP Member
4,210
24,567
Nov 2023
San Francisco, CA
Apr 24, 2026 at 12:39 PM#17
Dr.PathRoch said:
The useful move here is to separate what is established from what is widely repeated.

Same pattern here, and in the same order. The detail I would add is minor and it is already implied above.

Last edited: Apr 24, 2026 at 6:39 PM
30 5JessicaM_2024, TomFromTexas, mike.trainer_LA and 27 others
Reply Quote Save Share Report
anders_CPH
Senior Member
1,567
7,234
Feb 2024
Copenhagen, DK
Apr 25, 2026 at 12:37 AM#18
Dr.PathRoch said:
The useful move here is to separate what is established from what is widely repeated.

Coming at Dr.PathRoch’s question from a different direction. The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either. Those three things can all be true at once, and most arguments here are two people holding different parts of that.

29 4AussieAnna, BethLabQueen, ChrisMacros and 26 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Apr 25, 2026 at 12:34 PM#19

One concrete data point for the thread. One practical note: write down what you did and when, before you need it. Reconstructing a timeline from memory three months later is how people end up unable to answer the one question that would have resolved it.

28 3bri_stats, pete_manc_UK, anna.melb_AU and 25 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Apr 26, 2026 at 12:32 AM#20

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. No action needed from anybody.

6 6PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 3 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register